在BCR中的新ABL1激酶域突变:ABL1-阳性急性淋巴细胞白血病
Zixuan Li1, Danyue Peng1, Jun Deng1
1Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cancer medicine
|October 23, 2024
概括
新的ABL1激酶域 (ABL1 KD) 突变在BCR::ABL1阳性急性淋巴细胞白血病 (ALL) 中普遍存在. 这些突变影响了氨酸激酶抑制剂 (TKI) 耐药性,需要针对性治疗以改善患者的治疗结果.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 氨酸激酶抑制剂 (TKI) 对于治疗BCR::ABL1阳性白血病至关重要.
- ABL1激酶域 (ABL1 KD) 突变可以导致TKI耐药性.
- 与慢性髓性白血病 (CML) 相比,在BCR::ABL1-阳性急性淋巴细胞白血病 (ALL) 中,ABL1 KD突变的研究较少.
研究的目的:
- 分析BCR::ABL1-阳性ALL的成年人中的ABL1 KD突变.
- 研究ABL1KD突变与TKI选择之间的关系.
- 识别新型突变及其临床影响.
主要方法:
- 下一代测序 (NGS) 用于分析ABL1 KD突变.
- 从97名新诊断出BCR::ABL1阳性ALL的成年人中采集了样本.
- 在治疗前,细胞遗传完全缓解和复发阶段分析了突变.
主要成果:
- 新的ABL1KD突变 (R239G,F401V/L,R516L,K262T) 在治疗前和缓解期间普遍存在.
- 在复发时,T315I/P和P环突变更常见.
- 新的突变赋予了意马替尼抗药性,但对olverembatinib敏感,这改善了分子反应.
结论:
- 新的ABL1 KD突变在BCR::ABL1-阳性ALL中很常见.
- 这些突变会影响TKI的疗效和治疗策略.
- 针对性治疗对于管理TCI耐药ALL至关重要.
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
02:23Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
01:20The Retinoblastoma Gene
4.1K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.1K